Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

被引：9
|
作者：
Vij, Ravi [1 ]
Martin, Thomas G., III [2 ]
Nathwani, Nitya [3 ]
Fiala, Mark A. [1 ]
Gao, Feng [1 ]
Deol, Abhinav [4 ]
Buadi, Francis K. [5 ]
Kaufman, Jonathan L. [6 ]
Hofmeister, Craig C. [6 ,7 ]
Gregory, Tara K.
Berdeja, Jesus G.
Chari, Ajai
Rosko, Ashley E. [8 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Wayne State Univ, Detroit, MI USA
[5] Mayo Clin, Rochester, MN USA
[6] Emory Univ, Sch Med, Atlanta, GA USA
[7] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Sch Med, Atlanta, GA USA
[8] Colorado Blood Canc Inst, Denver, CO USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130644
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
602
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [41] Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
    McCarthy, Philip L.
    Holstein, Sarah A.
    Petrucci, Maria Teresa
    Richardson, Paul G.
    Hulin, Cyrille
    Tosi, Patrizia
    Bringhen, Sara
    Musto, Pellegrino
    Anderson, Kenneth C.
    Caillot, Denis
    Gay, Francesca
    Moreau, Philippe
    Marit, Gerald
    Jung, Sin-Ho
    Yu, Zhinuan
    Winograd, Benjamin
    Knight, Robert D.
    Palumbo, Antonio
    Attal, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3279 - +
  • [42] Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial
    Puig, Noemi
    Hernandez, Miguel T.
    Dachs, Laura Rosinol
    Garcia, Esther Gonzalez
    De Arriba, Felipe
    Oriol, Albert
    Gonzalez-Calle, Veronica
    Escalante, Fernando
    De La Rubia, Javier
    Meda, Mercedes Gironella
    Tamayo, Rafael Rios
    Sanchez, Ricarda Belen Garcia
    Perez, Jose Maria Arguinano
    Amor, Adrian Alegre
    Martin, Jesus
    Gutierrez, Norma C.
    Calasanz, Maria Jose
    Martin-Ramos, Maria Luisa
    Caro, Maria del Carmen Couto
    Casanova, Maria
    Arnao, Mario
    Persona, Ernesto Perez
    Lopez, Sebastian Garzon
    Gonzalez, Marta Sonia
    Sanchez, Guillermo Martin
    Rossi, Adriana C.
    Coleman, Morton
    Encinas, Cristina
    Lopez, Ana Maria Vale
    Teruel, Ana Isabel
    Paiva, Bruno
    Romero, Maria Teresa Cedena
    San-Miguel, Jesus
    Lahuerta, Juan Jose
    Blade, Joan
    Niesvizky, Ruben
    Mateos, Maria-Victoria
    BLOOD, 2019, 134
  • [43] Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study
    Larocca, Alessandra
    Corradini, Paolo
    Mina, Roberto
    Cascavilla, Nicola
    Liberati, Anna Marina
    Pescosta, Norbert
    Petrucci, Maria Teresa
    Ciccone, Giovannino
    Capra, Andrea
    Patriarca, Francesca
    Scalabrini, Delia Rota
    Innao, Vanessa
    Poggiu, Marco
    Cea, Michele
    Zambello, Renato
    Baraldi, Anna
    Belotti, Angelo
    Cellini, Claudia
    Galli, Monica
    Grasso, Mariella
    Aquino, Sara
    Casaluci, Gloria Margiotta
    De Sabbata, Giovanni
    Ballanti, Stelvio
    Offidani, Massimo
    Mancuso, Katia
    Boccadoro, Mario
    Bringhen, Sara
    BLOOD, 2019, 134
  • [44] Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
    Derman, Benjamin A.
    Cooperrider, Jennifer H.
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Major, Ajay
    Karrison, Theodore
    Jiang, Ken
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    BLOOD, 2023, 142
  • [45] Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands
    Uyl-de Groot, Carin A.
    Ramsden, Rachel
    Boersma, Janneke
    Zweegman, Sonja
    Dhanasiri, Sujith
    BLOOD, 2018, 132
  • [46] Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
    Marc-Andrea Baertsch
    Jana Schlenzka
    Elias K. Mai
    Maximilian Merz
    Jens Hillengaß
    Marc S. Raab
    Dirk Hose
    Patrick Wuchter
    Anthony D. Ho
    Anna Jauch
    Thomas Hielscher
    Christina Kunz
    Steffen Luntz
    Stefan Klein
    Ingo G. H. Schmidt-Wolf
    Martin Goerner
    Martin Schmidt-Hieber
    Peter Reimer
    Ullrich Graeven
    Roland Fenk
    Hans Salwender
    Christof Scheid
    Axel Nogai
    Mathias Haenel
    Hans W. Lindemann
    Hans Martin
    Richard Noppeney
    Katja Weisel
    Hartmut Goldschmidt
    BMC Cancer, 16
  • [47] Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
    Baertsch, Marc-Andrea
    Schlenzka, Jana
    Mai, Elias K.
    Merz, Maximilian
    Hillengass, Jens
    Raab, Marc S.
    Hose, Dirk
    Wuchter, Patrick
    Ho, Anthony D.
    Jauch, Anna
    Hielscher, Thomas
    Kunz, Christina
    Luntz, Steffen
    Klein, Stefan
    Schmidt-Wolf, Ingo G. H.
    Goerner, Martin
    Schmidt-Hieber, Martin
    Reimer, Peter
    Graeven, Ullrich
    Fenk, Roland
    Salwender, Hans
    Scheid, Christof
    Nogai, Axel
    Haenel, Mathias
    Lindemann, Hans W.
    Martin, Hans
    Noppeney, Richard
    Weisel, Katja
    Goldschmidt, Hartmut
    BMC CANCER, 2016, 16
  • [48] Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial
    Goldschmidt, Hartmut
    Mai, Elias K.
    Bertsch, Uta
    Besemer, Britta
    Haenel, Mathias
    Miah, Kaya
    Fenk, Roland
    Schlenzka, Jana
    Munder, Markus
    Duerig, Jan
    Blau, Igor Wolfgang
    Huhn, Stefanie
    Hose, Dirk
    Jauch, Anna
    Kunz, Christina
    Neubauer, Andreas
    Scheid, Christof
    Schroers, Roland
    von Metzler, Ivana
    Schieferdecker, Aneta
    Thomalla, Joerg
    Reimer, Peter
    Mahlberg, Rolf
    Graeven, Ullrich
    Kremers, Stephan
    Martens, Uwe M.
    Kunz, Christian
    Hensel, Manfred
    Seidel-Glaetzer, Andrea
    Weisel, Katja
    Raab, Marc-Steffen
    Salwender, Hans
    BLOOD, 2021, 138
  • [49] RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
    Luoma, Sini
    Anttila, Pekka
    Saily, Marjaana
    Lundan, Tuija
    Heiskanen, Jouni
    Siitonen, Timo
    Kakko, Sakari
    Putkonen, Mervi
    Ollikainen, Hanna
    Terava, Venla
    Sankelo, Marja
    Partanen, Anu
    Launonen, Kirsi
    Rasanen, Anu
    Sikio, Anu
    Suominen, Merja
    Bazia, Piotr
    Kananen, Kristiina
    Lievonen, Juha
    Selander, Tuomas
    Pelliniemi, Tarja-Terttu
    Ilveskero, Sorella
    Huotari, Virva
    Mantymaa, Pentti
    Tienhaara, Anri
    Jantunen, Esa
    Silvennoinen, Raija
    ANNALS OF HEMATOLOGY, 2019, 98 (12) : 2781 - 2792
  • [50] Limite d b enefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea
    Byun, Ja Min
    Kim, Sang-A
    Koh, Youngil
    Shin, Dong-Yeop
    Kwon, Ji Hyun
    Kim, Jin Seok
    Kim, Kihyun
    Min, Chang-Ki
    Eom, Hyeon-Seok
    Lee, Je-Jung
    Bang, Soo-Mee
    Yoon, Sung-Soo
    CURRENT PROBLEMS IN CANCER, 2022, 46 (01)
12345